Clinical pharmacology of adinazolam and
β
J. C. Fleishaker; L. K. Hulst; T. C. Smith; H. Friedman
π
Article
π
1992
π
Springer
π
English
β 860 KB
The tolerability, pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam (NDMAD) were assessed following intravenous infusions of 5, 10, 15, and 20 mg adinazolam mesylate, 10, 20, 30 and 40 mg NDMAD mesylate, and placebo. Six subjects per dose level received treatments in a do